Current and future status of adjuvant therapy for breast cancer (Q35053975)

6 August 2017

1 reference

title

Current and future status of adjuvant therapy for breast cancer (English)

1 reference

6 August 2017

Robert E Coleman

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

issue

3 Suppl

1 reference

6 August 2017

page(s)

880-886

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Ovarian ablation as adjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Use of bisphosphonates for the treatment of bone metastasis in experimental animal models

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

A high incidence of vertebral fracture in women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Long-term sequelae from adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11124

7 January 2021

Identifiers

DOI

10.1002/CNCR.11124

1 reference

6 August 2017

1 reference